Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DP-QB-MYA-002 Phage Cocktail for MDR Mycobacterium Abscessus Pulmonary Infection
NCT07429162Phase 1Not yet recruiting
- Sponsor
- Alberta Health Services
- Start
- Jul 2026
- Primary completion
- Jul 2027
- Modality
- Microbiome Therapeutics
01
Overview
Phase 1, open-label, single-arm trial of DP-QB-MYA-002 in Mycobacterium abscessus pulmonary disease, sponsored by Alberta Health Services. Primary endpoint: Time to Sputum Culture Conversion at 1 year. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
DP-QB-MYA-002
03
Conditions
Mycobacterium abscessus pulmonary disease
Beyond the preview
Go deeper on NCT07429162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07429162.